Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 07 2021 - 4:10PM
Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company
developing treatments for degenerative genetic disorders, today
reported that João Siffert, M.D., president and chief executive
officer, will participate in a fireside chat during the Goldman
Sachs 42nd Annual Global Healthcare Conference on Wednesday, June
9, 2021 at 1:20 p.m. ET.
The live webcast will be available in the investor section of
the company's website at www.designtx.com. The webcast will be
archived for 60 days following the presentation.
About Design TherapeuticsDesign Therapeutics is
a biotechnology company developing a new class of therapies based
on a platform of gene targeted chimera (GeneTAC™) small molecules.
Our GeneTAC molecules are designed to either turn on or turn off a
specific disease-causing gene to address the underlying cause of
disease. The company’s lead program is focused on the treatment of
Friedreich ataxia, followed by a program in myotonic dystrophy
type-1 and discovery efforts for multiple other serious
degenerative disorders caused by nucleotide repeat expansions. For
more information, please visit designtx.com.
Contact: Alicia DavisTHRUST Strategic
Communications(910) 620-3302alicia@thrustsc.com
Design Therapeutics (NASDAQ:DSGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Design Therapeutics (NASDAQ:DSGN)
Historical Stock Chart
From Apr 2023 to Apr 2024